Gavi Board approves COVAX Buffer for high-risk groups in humanitarian settings
5% of the total number of available doses procured through the COVAX Facility will be allocated to the COVAX Buffer.
COVAX publishes first round of allocations
Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…
COVAX Statement on WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine
Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…
COVAX Statement on New Variants of SARS-CoV-2
The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.
COVAX publishes first interim distribution forecast
Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…
Gavi statement on AstraZeneca/Oxford interim efficacy data
Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.
COVAX Facility convenes first meeting of COVAX Shareholders Council
The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.
COVAX welcomes appointment of civil society representatives
As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…
Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.
Gavi applauds G20 Leaders' commitment to supporting the global effort against COVID-19
Gavi, the Vaccine Alliance applauds the commitment of the G20 Leaders chaired by Saudi Arabia “to provide immediate resources to the WHO’s…
Gavi Board calls for bold engagement to respond to COVID-19
With the COVID-19 pandemic already affecting 47 Gavi-supported countries, Gavi, the Vaccine Alliance has already taken new steps to help strengthen the preparedness of health systems in lower-income countries with the full support of its Board.…
Last updated: 25 Nov 2019